Clinical & Translational Oncology最新文献

{"title":"Gastric cancer burden and regional disparities among Helicobacter pylori-positive patients in the Americas: a systematic review and meta-analysis.","authors":"Francisco Cezar Aquino de Moraes, Luis Eduardo Rodrigues Sobreira, Nuris Maria Torres Argota, Emanuele Rocha da Silva, Gustavo Tadeu Freitas Uchôa Matheus, Rommel Mario Rodríguez Burbano","doi":"10.1007/s12094-025-04126-2","DOIUrl":"10.1007/s12094-025-04126-2","url":null,"abstract":"<p><strong>Background: </strong>Helicobacter pylori infection is a significant risk factor for gastric cancer (GC), particularly in populations across the Americas. Previous studies have suggested a link between HP and GC, but variability in prevalence across regions has yet to be fully explored. The aim of this study is to quantify the prevalence of GC in HP-positive patients across the Americas, identifying disparities by country, region, and demographic factors.</p><p><strong>Methods: </strong>The study followed the PRISMA guidelines and was registered with PROSPERO (CRD42024585790). A systematic search of PubMed, Scopus, LILACS/BVS, and Web of Science databases was conducted until August 20, 2024. Eligibility criteria included studies with patients aged 18 years or older, with confirmed diagnosis of gastric cancer, and H. pylori infection status. Risk of success was assessed using the Newcastle-Ottawa Scale, and publication success was assessed using the Egger test. Pooled prevalence was calculated using a meta-analysis of proportions with a random-effects model, and heterogeneity was assessed using the I² statistic. There was no funding for this study.</p><p><strong>Results: </strong>Fifty-nine studies, with 5,734,656 patients (134,755 HP-positive), met the inclusion criteria. The overall prevalence of GC in HP-positive patients in the Americas was 25.56% (95% CI: 20.72-30.40), with high heterogeneity (I2 = 100%, p < 0.05). South America showed a higher prevalence (27.66%, 95% CI: 22.36-32.96) than North America (23.47%, 95% CI: 20.72-30.40). Peru had the highest prevalence at 52.11%, followed by Chile (50.94%) and Honduras (45.62%); Colombia and the United States showed lower rates, at 15.65% and 23.02%, respectively.</p><p><strong>Conclusion: </strong>This meta-analysis highlights a significant GC prevalence among HP-positive patients in the Americas, with marked variability between countries.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1732-1746"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145551772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routine EUS-FNA.","authors":"Tomoya Ekawa, Kenji Ikezawa, Yoji Kukita, Makiko Urabe, Yugo Kai, Ryoji Takada, Takashi Akazawa, Yu Mizote, Kumiko Tatsumi, Shigenori Nagata, Hisataka Ogawa, Shinichiro Hasegawa, Hidenori Takahashi, Kazuyoshi Ohkawa, Hideaki Tahara","doi":"10.1007/s12094-025-04111-9","DOIUrl":"10.1007/s12094-025-04111-9","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the in vitro drug sensitivity of patient-derived cancer organoids (PDCOs) established from residual samples from saline flushes (RSSF) collected during routine endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in patients with pancreatic cancer.</p><p><strong>Methods: </strong>Organoids were cultured under mutation-selective conditions. IC₅₀ values for 5-fluorouracil (5-FU), SN-38, oxaliplatin, gemcitabine, and paclitaxel were calculated.</p><p><strong>Results: </strong>PDCOs showed variable responses to the drugs. Exploratory quantitative analysis using ordinal sensitivity scoring and ROC curves (Area under the curve [AUC] up to 0.917) indicated that lower in vitro IC₅₀ scores tended to associate with clinical responders (PR/uPR) compared with non-responders (progressive or stable disease [PD/SD]).</p><p><strong>Conclusions: </strong>This study demonstrated the feasibility and potential usefulness of in vitro drug sensitivity profiling of pancreatic cancer using RSSF-derived PDCOs. These findings represent the first step toward clinical application, and further validation in larger cohorts is warranted.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1940-1946"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors.","authors":"Juan Carlos Redondo-González, Luis Posado-Domínguez, Laura Corvo-Félix, Lorena Bellido Hernández, Iñigo San Miguel-Arregui, Emilio Fonseca-Sánchez, Alejandro Olivares-Hernández, Edel Del Barco-Morillo","doi":"10.1007/s12094-025-04142-2","DOIUrl":"10.1007/s12094-025-04142-2","url":null,"abstract":"<p><p>Immunotherapy has led to a paradigm shift in the treatment of various tumors. However, the results obtained sometimes show heterogeneous and inconsistent responses despite the presence of biomarkers such as PD-L1. Recent studies suggest that the efficacy of immunotherapy may vary based on sex, although the findings remain controversial. The aim of this comprehensive review is to evaluate the available evidence and the biological mechanisms that could explain these differences. Some recent meta-analyses have suggested a greater overall survival benefit for males. Theoretical models, supported by in vivo studies in different animal species, are currently focused on the implications of the tumor microenvironment, hormonal factors in the antitumor activity of the immune system and their correlation with the patient's sex. Other chromosomal sex-specific alterations could be influenced by epigenetic changes affecting genetic material. Prospective studies are needed to further investigate the uncertain relationship between sex and immunotherapy in humans.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1586-1594"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025).","authors":"Ferrán Losa, Olatz Etxaniz, Alejandra Giménez, Paula Gomila, Lara Iglesias, Federico Longo, Esteban Nogales, Antonio Sánchez, Gemma Soler, Isaura Fernández","doi":"10.1007/s12094-026-04241-8","DOIUrl":"10.1007/s12094-026-04241-8","url":null,"abstract":"<p><p>Cancer of unknown primary (CUP) is defined as a heterogeneous group of tumors that appear as metastases for which a standard diagnostic work-up fails to identify the tissue of origin. There is now high-level evidence showing that actionable genomic alterations should be routinely determined in patients with CUP to enable molecularly guided therapy as appropriate. In this guideline (updated in 2025), we summarize diagnostic processes and therapeutic options for CUP, as well as new developments in molecular medicine that will help to improve the poor outcomes associated with this unique disease entity.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1610-1623"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147437276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma.","authors":"Matthew K Wagar, Kharmen Bharucha, Lauren Montemorano, Laura B Huffman, Amy L Godecker, Lisa M Barroilhet","doi":"10.1007/s12094-025-04105-7","DOIUrl":"10.1007/s12094-025-04105-7","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize long-term (LT) and short-term (ST) responders to the Poly (ADP-ribose) polymerase inhibitor olaparib in the primary and recurrent maintenance setting.</p><p><strong>Methods: </strong>Clinical and molecular data was collected for patients receiving maintenance olaparib between January 2014 and July 2021. ST responders were defined as those experiencing progression < 6 months from initiating olaparib, whereas LT responders exhibited response ≥ 2 years. Molecular analysis included germline BRCA1/2 status, Myriad MyChoice CDx Homologous Recombination Deficiency (HRD) somatic testing, and STRATA Select comprehensive genomic profiling.</p><p><strong>Results: </strong>124 patients who received olaparib were included; 45 (36.3%) LT and 31 (25.0%) ST responders were identified. BRCA2 mutations were enriched among the LT responders compared to ST responders (16 (35.5%) v. 4 (12.9%), p = 0.028) and LT responders were more likely to be HRD (40 (88.9%) v 19 (61.3%), p = 0.005). Patients receiving olaparib following platinum-sensitive recurrence were more likely to experience ST response compared to the primary setting (24 (55.8%) vs 7 (21.2%), p = 0.002). In both the primary and recurrent setting, LT responders were more likely to have a complete response to the most recent chemotherapy when compared to those experiencing ST response (24 (92.3%) v. 3 (42.9%), for primary maintenance, p = 0.021 and 10 (52.6%) v. 3 (12.5%) for recurrent, p = 0.004).</p><p><strong>Conclusions: </strong>LT response to olaparib for primary maintenance is common, and more frequently observed in patients with a complete response to platinum-based chemotherapy. BRCA2 mutations conferred exceptional benefit to olaparib. Durable benefit was more commonly observed in patient's receiving frontline maintenance olaparib.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1673-1682"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.","authors":"Xueqing Sun, Jing Xue, Zhen Sun, Wei Tian, Xiao Song, Ran Chu, Ming Liu","doi":"10.1007/s12094-025-04089-4","DOIUrl":"10.1007/s12094-025-04089-4","url":null,"abstract":"<p><strong>Background: </strong>Endometrial carcinoma (EC) molecular subtypes are critical for risk assessment and treatment guidance, with strong prognostic implications.</p><p><strong>Objectives: </strong>To investigate associations between EC molecular subtypes and high-risk pathological factors to optimize individualized therapy.</p><p><strong>Design: </strong>Multicenter retrospective cohort study.</p><p><strong>Methods: </strong>Retrospective analysis of 292 EC cases classified via the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) into four subtypes: POLE ultramutant (POLE-mut), mismatch repair deficient (MMRd), p53 abnormal (p53 abn), and p53 wild-type (p53 wt). Associations with clinicopathological parameters were assessed using chi-square tests and logistic regression.</p><p><strong>Results: </strong>Among the 292 patients, the distribution of molecular subtypes was as follows: POLE-mut (6.8%), MMRd (21.2%), p53 abn (14.4%), and p53 wt (57.5%). Molecular subtypes correlated significantly with International Federation of Gynecology and Obstetrics (FIGO) stage (p < 0.001), poor/undifferentiated histology (p < 0.001), and lymphovascular space invasion (LVSI) (p = 0.001). The POLE-mut and p53 wt were predominantly enriched in stage I disease (90.0% and 80.4%, respectively). In contrast, the majority of p53 abn were classified as stage II (81.0%). The MMRd subtype was distributed across all stages. Advanced stages (III-IV) were most frequently observed in the p53 abn and MMRd subtypes. p53 abn showed the highest rate of poor/undifferentiated histology (61.9%). MMRd comprised the largest proportion of LVSI-positive cases (39.1%). Multivariate analysis identified MMRd as an independent predictor of LVSI (p = 0.001), while both MMRd (p = 0.009) and p53 abn (p < 0.001) independently predicted poor/undifferentiated histology.</p><p><strong>Conclusions: </strong>EC molecular subtypes stratify clinicopathological risk and predict tumor behavior, highlighting their potential utility in informing individualized management. These findings suggest possible roles ranging from treatment de-escalation (POLE‑mut) to treatment intensification (p53‑abn), although further prospective studies are needed before routine clinical implementation.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1662-1672"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anxiety in breast cancer research (1982-2024): a bibliometric analysis.","authors":"Jie Hou, Yaqin Meng, Lei Zhang, Haixia Fan, Minheng Zhang","doi":"10.1007/s12094-025-04115-5","DOIUrl":"10.1007/s12094-025-04115-5","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a major global malignancy, with anxiety severely impacting patients' quality of life and treatment outcomes. Understanding evolving research trends is critical for developing effective interventions. This study examines 40-year trends, collaborations, and knowledge structures in breast cancer anxiety research. The goal is to inform future directions for psychosocial oncology research and policymaking.</p><p><strong>Methods: </strong>Articles and reviews related to breast cancer and anxiety were retrieved from the Web of Science Core Collection (WoSCC). Medical Subject Headings (MeSH) and corresponding entry terms were employed to optimize the search strategy. CiteSpace (Version 6.4.R1), VOSviewer (Version 1.6.19), and the Bibliometrix R package were used to construct knowledge maps, visualize collaboration networks, monitor journal and author metrics over time, and calculate key indicators such as publication and citation counts. Regression analysis was applied to predict future development trends.</p><p><strong>Results: </strong>Analysis of 4376 publications revealed a surge in research post-2006, peaking at 316 publications in 2021. The United States led in publications (1333 articles) and citations (56,008), followed by China, England, and Canada. The University of Sydney ranked first institutionally, and Christine Miaskowski was the most influential author. Psycho-Oncology and Supportive Care in Cancer were the leading journals. Co-citation and reference clustering identified key themes, including the psychological impact of COVID-19, psychological interventions, and long-term survivorship. Keyword analysis revealed a consistent focus on terms such as \"cancer survivor\" and \"mental health,\" with recent trends in \"telehealth,\" \"digital interventions,\" and \"mindfulness.\"</p><p><strong>Conclusion: </strong>Our analysis confirms a paradigm shift toward psychosocial and digital health interventions in breast cancer anxiety research. The findings advocate for integrated, patient-centered care models and highlight untapped potential in low-resource regions. Future research should prioritize scalable digital tools to address global disparities.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1637-1651"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management.","authors":"Abdul Wasai, Adhiraj Roy, Deepti Pandita","doi":"10.1007/s12094-025-04121-7","DOIUrl":"10.1007/s12094-025-04121-7","url":null,"abstract":"<p><p>Prostate adenocarcinoma (PAC) ranks second as most lethal malignancy in men worldwide with significant economic burden on public health management. Despite of cytoreductive surgery of visible tumor mass followed by administration of chemotherapies including androgen deprivation therapy (ADT) using several drugs including enzalutamide, patients develop therapy resistance displaying metastatic, castration-resistant PAC (mCRPC). Furthermore, mCRPC patients fail to respond to neoadjuvant chemotherapies (NACT) such as androgen receptor-targeted agents (ARTAs) and develop a lethal, highly aggressive, therapy-induced neuroendocrine PAC (NEPC). Hence, identification of novel, targetable drivers and therapeutic interventions are highly warranted to manage this lethal pathology. Recently, nanotheranostics, an approach combining cancer diagnostics and therapeutics via nanotechnology is emerging as a promising intervention strategy towards early detection, disease remission and improved PAC patient survival outcomes. It frequently targets interacting components between cancer cells and tumor microenvironment (TME) which play critical role in disease progression and chemoresistance. For example, multimodal peptide-based imaging probes (peptides complexed with Cu⁶⁴ etc.) combined with PET-MRI improved early PAC detection and patient survival. In this review, we have comprehensively discussed recent developments in cancer nanotheranostics-their targets in PAC TME, mode of actions and potential therapeutic strategies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1484-1500"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145551805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroactive ligand-receptor interaction in gastric cancer: a comprehensive spatial single-cell analysis.","authors":"Lirong Chen, Xiao Li, Shaocong Mo, Shenyang Zhao, Jiayue Zheng, Kexin Cheng, Yi Zhang, Feifei Luo, Wanwei Zheng","doi":"10.1007/s12094-025-04114-6","DOIUrl":"10.1007/s12094-025-04114-6","url":null,"abstract":"<p><strong>Background: </strong>Neuroactive ligand-receptor interaction may influence the development of gastric cancer. However, the underlying mechanisms have not been elucidated.</p><p><strong>Methods: </strong>Based on single-cell, spatial transcriptome, bulk transcriptome data and immunofluorescence in gastric cancer, we validated cells associated with neuroactive ligand-receptor interaction pathways, prognostic genes and communication signaling direction at spatial level.</p><p><strong>Results: </strong>Neuroactive ligand-receptor interaction gene set was closely related to monocyte-macrophages (Mono-Macs), which with high expression of neuroactive ligand-receptor interaction gene set (NEUROhighMono) had significant communication interactions with immune and endothelial cells. Prognostic modeling indicated that patients with high pathway activity had poorer outcomes, characterized by higher stromal scores and elevated immune checkpoint levels. Among related genes, CHRNE was identified as a key marker of poor prognosis, predominantly expressed in Mono-Macs. Integrated spatial transcriptome and immunofluorescence further demonstrated that CHRNE-positive Mono-Macs (CHRNE + Mono) may promote tumor angiogenesis through VEGFA, linking CHRNE to tumor progression and unfavorable prognosis.</p><p><strong>Conclusions: </strong>This study explored neuroactive ligand-receptor interactions in gastric cancer, revealing that Mono-Macs were significantly influenced by related genes. CHRNE + Mono may regulate tumor microenvironment by promoting angiogenesis, highlighting CHRNE as a potential driver of tumor progression. These findings suggest that neuroactive ligand-receptor interactions, particularly CHRNE, could offer potential therapeutic strategies for gastric cancer.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1718-1731"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the predictive role of inflammatory indices in cancer metastasis.","authors":"Mohammad Reza Moghaddasnejad, Tina Vosoughi, Negar Sadat Sherafat, Saeid Bitaraf, Najmaldin Saki","doi":"10.1007/s12094-025-04093-8","DOIUrl":"10.1007/s12094-025-04093-8","url":null,"abstract":"<p><strong>Background: </strong>Early detection of metastasis in cancer patients plays a pivotal role in improving treatment outcomes and increasing patient survival. This study aimed to evaluate the predictive role of inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune inflammation index (SII), and systemic inflammation response index (SIRI), in identifying metastatic status.</p><p><strong>Methods: </strong>In this study, 60 cancer patients were enrolled between December 2023 and June 2024. Clinicopathological data and complete blood counts (CBCs) were collected prior to treatment initiation. The Receiver Operating Characteristic (ROC) curve was used to determine the optimal cutoff values of different baseline inflammatory indices for the metastatic status analysis.</p><p><strong>Results: </strong>The levels of inflammatory indices were greater in metastatic patients than in nonmetastatic patients; however, only the SIRI was significantly different (1.04 [0.76-1.69] vs. 0.71 [0.45-1.07]; P = 0.044). ROC curve analysis revealed that the area under the curve (AUC) for the SIRI was 0.652 (95% CI 0.507-0.797). Furthermore, broader combinations of the SIRI and MLR, either individually or in conjunction with the NLR, PLR, and/or SII, yielded multi-index models with greater discriminatory power and maintained statistical significance (p < 0.05).</p><p><strong>Conclusion: </strong>The findings indicate that the SIRI, in combination with the MLR, plays a significant role in predicting the metastatic status of cancer patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1853-1860"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145453803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}